Zelgen Pharmaceuticals released its 2026 interim report, with net profit attributable to the parent company reaching 640 million yuan. During the reporting period, total operating revenue was 1.205 billion yuan, and net cash flow from operating activities was 809 million yuan. The company's latest asset-liability ratio stands at 51.21%, gross margin at 94.64%, down 2.37 percentage points from the previous quarter, ROE at 37.20%, and diluted earnings per share at 2.42 yuan. In addition, total asset turnover was 0.37 times, inventory turnover was 0.35 times, the number of shareholders was 13,700, and the top ten shareholders held 42.50% of the total share capital.
Suzhou Zelgen Biopharmaceuticals Co LtdReports strong interim profit of 640 million yuan and high margins, indicating solid financial performance.